Company intelligence / Profile preview

Biophagy

Mountainair, New Mexico, United Statesbiophagy.com ↗

Ownership: Private
Employees: ~1
Development stage: Preclinical

Overview

Biophagy is developing proprietary compounds that stimulate or modulate autophagy. The company’s initial work has focused on in vitro models with plans to advance to in vivo studies followed by lead identification and pre-clinical evaluation. They are also developing an over-the-counter/direct-to-consumer product called CellWatch™, which combines a rationally designed mix of autophagy stimulants with a unique method to measure individual physiological response.

Therapeutic areas: OtherNeurologyInfectious Diseases
Modalities: Small molecules (autophagy stimulants and modulators)OTC/DTC supplement products
Industry: Biotech

Partnerships

Seeking partnerships with large/mid-sized pharma companies; none announced yet.

Beyond the preview

Go deeper on Biophagy.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biophagy.

Explore the full profile